Association Between Genetic Polymorphisms In
TYMS
case-control study
gene variant
glioma
susceptibility
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
06
2019
accepted:
10
09
2019
entrez:
22
10
2019
pubmed:
22
10
2019
medline:
22
10
2019
Statut:
epublish
Résumé
Thymidylate synthase ( This case-control study included 605 patients and 1300 cancer-free individuals. Genotyping was performed using Sequenom Mass-ARRAY. We determined odds ratios (ORs) and their 95% confidence intervals (CIs) to estimate the correlations. The analysis revealed that rs1059394 TT and CT+TT genotype had significantly low glioma risk (TT to CC: OR = 0.71, 95% CI = 0.52-0.97, Our study provides evidence of the effect of
Sections du résumé
BACKGROUND
BACKGROUND
Thymidylate synthase (
METHODS
METHODS
This case-control study included 605 patients and 1300 cancer-free individuals. Genotyping was performed using Sequenom Mass-ARRAY. We determined odds ratios (ORs) and their 95% confidence intervals (CIs) to estimate the correlations.
RESULTS
RESULTS
The analysis revealed that rs1059394 TT and CT+TT genotype had significantly low glioma risk (TT to CC: OR = 0.71, 95% CI = 0.52-0.97,
CONCLUSION
CONCLUSIONS
Our study provides evidence of the effect of
Identifiants
pubmed: 31632074
doi: 10.2147/OTT.S221204
pii: 221204
pmc: PMC6790345
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8241-8247Informations de copyright
© 2019 Yao et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3415-3425
pubmed: 30583664
Pharmacogenetics. 2004 May;14(5):319-27
pubmed: 15115918
Neurosurg Clin N Am. 2019 Jan;30(1):1-16
pubmed: 30470396
Hum Genet. 1990 Oct;85(6):576-80
pubmed: 2227947
Int J Epidemiol. 2013 Jun;42(3):792-802
pubmed: 23657200
J Biol Chem. 2017 Aug 11;292(32):13449-13458
pubmed: 28634233
Oncotarget. 2016 Nov 22;7(47):78110-78118
pubmed: 27801669
Cancer Manag Res. 2018 Apr 26;10:867-872
pubmed: 29731666
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Cell Mol Neurobiol. 2017 Mar;37(2):263-274
pubmed: 27055523
Neuro Oncol. 2017 Jul 1;19(7):930-939
pubmed: 28387849
Eur J Cancer. 2015 Oct;51(15):2231-2241
pubmed: 26421825
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Nat Genet. 2007 Mar;39(3):347-51
pubmed: 17293865
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Curr Protoc Hum Genet. 2009 Jan;Chapter 2:Unit 2.12
pubmed: 19170031
Mol Carcinog. 2015 Sep;54(9):880-8
pubmed: 24756984
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Mol Carcinog. 2015 Apr;54(4):281-90
pubmed: 24166930
Nature. 2018 Sep;561(7724):S50-S51
pubmed: 30258163
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Prog Mol Biol Transl Sci. 2011;98:187-234
pubmed: 21199773
Int J Mol Sci. 2018 Aug 21;19(9):null
pubmed: 30134598
Oncol Lett. 2015 Sep;10(3):1569-1574
pubmed: 26622711
J Pers Med. 2018 Dec 13;8(4):null
pubmed: 30551678
Cancer Cell Int. 2019 Jan 8;19:11
pubmed: 30636932
Tumour Biol. 2015 Sep;36(9):7151-7
pubmed: 25877757
Curr Probl Cancer. 2019 Feb;43(1):66-74
pubmed: 30180988